An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma
Renata Sano(Children's Hospital of Philadelphia), Yaël P. Mossé(Children's Hospital of Philadelphia)
Cited by 68
Related Papers
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
|Nature Medicine|2023|125
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
|Clinical Cancer Research|2018|88
Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
|Cancer Research|2021|70
Safety and efficacy of tandem <sup>131</sup>I‐metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma
|Pediatric Blood & Cancer|2011|61